scholarly journals Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Wassim Elyaman ◽  
Samia J. Khoury ◽  
David W. Scott ◽  
Anne S. De Groot

The induction of immunologic tolerance is an important clinical goal in autoimmunity. CD4+regulatory T (Treg) cells, defined by the expression of the transcription factor forkhead box P3 (FoxP3), play a central role in the control of autoimmune responses. Quantitative and qualitative defects of Tregs have been postulated to contribute to failed immune regulation in multiple sclerosis (MS) and other autoimmune diseases. This paper highlights the potential uses of T regulatory cell epitopes (Tregitopes), natural Treg epitopes found to be contained in human immunoglobulins, as immunomodulating agents in MS. Tregitopes expand Treg cells and induce “adaptive Tregs” resulting in immunosuppression and, therefore, are being considered as a potential therapy for autoimmune diseases. We will compare Tregitopes versus intravenous immunoglobulin (IVIg) in the treatment of EAE with emphasis on the potential applications of Tregitope for the treatment of MS.

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Jiani Li ◽  
Jichao Sha ◽  
Liwei Sun ◽  
Dongdong Zhu ◽  
Cuida Meng

Regulatory T (Treg) cells are a subtype of CD4+ T cells that play a significant role in the protection from autoimmunity and the maintenance of immune tolerance via immune regulation. Epigenetic modifications of Treg cells (i.e., cytosine methylation at the promoter region of the transcription factor, Forkhead Box P3) have been found to be closely associated with allergic diseases, including allergic rhinitis, asthma, and food allergies. In this study, we highlighted the recent evidence on the contribution of epigenetic modifications in Treg cells to the pathogenesis of allergic diseases. Moreover, we also discussed directions for future clinical treatment approaches, with a particular emphasis on Treg cell-targeted therapies for allergic disorders.


2010 ◽  
Vol 8 (5) ◽  
pp. 121
Author(s):  
V. Uva ◽  
L. Sfondrini ◽  
T. Triulzi ◽  
P. Casalini ◽  
R. Orlandi ◽  
...  

Author(s):  
Behnaz Esmaeili ◽  
Parvin Mansouri ◽  
Alipasha Meysamie ◽  
Maryam Izad

Memory regulatory T cells (Tregs) has been demonstrated to produce IL-17 in Psoriasis. Forkhead box P3 (Foxp3) has been demonstrated not to be reliable marker to evaluate Treg cells. Effector CD4+T cells also express Foxp3 after activation. Human T helper-17 cells (Th-17) express high level of surface CD26, while regulatory T cells are CD26 negative or low and this phenotype is stable even after activation of Treg cells. In this study, we aimed to analyze IL-17 producing Treg cells using CD26.      Memory T cells were isolated from 10 patients with psoriasis and 10 controls. Ex vivo stimulated IL-17 producing regulatory (Forkhead Box P3 (Foxp3)+CD25+CD26-/low) and effector (Foxp3+CD25+CD26hi) memory T cells were analyzed by flow cytometry. IL-23, IL-6, TNFα, TGFβ and IL-17 cytokine levels were also evaluated. No significant difference in IL-17+memory regulatory T cells was seen between patients and controls (p=0.19). A significant decrease in the percentage of IL-17 producing CD26hi effector memory T cells was observed in patients (p=0.04). However, the percentage of these cells was not different between patients with mild or severe form of psoriasis compared to controls (p=0.13). We could not find any significant difference regarding IL-23, IL-6, TNFα, TGFβ and IL-17 cytokine levels in plasma and cell culture supernatant samples between patients and controls.  Taken together, our results showed a reduced IL-17 producing effector memory CD26hi T cells in patients with psoriasis compared to controls. However, IL-17 producing memory regulatory CD4+T cells of patients showed no significant difference from that of controls


2020 ◽  
Vol 21 (6) ◽  
pp. 2233
Author(s):  
David Sanz-Rubio ◽  
Arianne Sanz ◽  
Luis Varona ◽  
Rosa Bolea ◽  
Marta Forner ◽  
...  

Background: Epigenetic changes in obstructive sleep apnea (OSA) have been proposed as a mechanism for end-organ vulnerability. In children with OSA, Forkhead Box P3 (FOXP3) DNA methylation were associated with inflammatory biomarkers; however, the methylation pattern and its effect in the expression of this gene have not been tested in adults with OSA. Methods: Plasma samples from subjects without comorbid conditions other than OSA were analyzed (the Epigenetics Status and Subclinical Atherosclerosis in Obstructive Sleep Apnea (EPIOSA) Study: NCT02131610). In 16 patients with severe OSA (Apnea-Hypopnea Index—AHI- > 30 events/h) and seven matched controls (AHI < 5), methylation of FOXP3 gen was evaluated by PCR of the promoter and by pyrosequencing of the intron 1 Treg-specific demethylated region (TSDR). In another 74 patients with OSA (AHI > 10) and 31 controls, we quantified FOXP3 protein expression by ELISA and gene expression by quantitative real-time PCR. C-reactive protein (CRP) and plasma Treg cells were also evaluated. Results: Neither the levels of the promoter nor the TSDR demethylated region were different between controls and patients with OSA, whether they were grouped by normal or high CRP. FOXP3 protein and mRNA expression did not differ between groups. Conclusions: FOXP3 methylation or its expression is not altered in adults with OSA, whatever their inflammatory status.


2013 ◽  
Vol 319 (5) ◽  
pp. 731-739 ◽  
Author(s):  
Janka Held-Feindt ◽  
Kirsten Hattermann ◽  
Susanne Sebens ◽  
Stefan Krautwald ◽  
H.Maximilian Mehdorn ◽  
...  

2013 ◽  
Vol 4 ◽  
Author(s):  
Sfondrini Lucia ◽  
Cataldo Alessandra ◽  
Uva Valentina ◽  
Triulzi Tiziana ◽  
Casalini Patrizia ◽  
...  

2018 ◽  
Vol 26 ◽  
pp. 252
Author(s):  
Z.A. Aljawadi ◽  
M.A.n. Kashmoola ◽  
A.M. Almahdawi ◽  
A.R. Al-derzi ◽  
B.A. Abdul-majeed

2019 ◽  
Vol 14 (3) ◽  
pp. 543-553 ◽  
Author(s):  
Mei Ding ◽  
Johan Brengdahl ◽  
Madelene Lindqvist ◽  
Ulf Gehrmann ◽  
Elke Ericson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document